

InspireMD, Inc.  
Form 8-K  
October 03, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): September 27, 2012

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

Delaware                      000-54335                      26-2123838  
(State or other jurisdiction (Commission File Number) (IRS Employer  
of incorporation)                      Identification No.)

4 Menorat Hamaor St.                      67448  
Tel Aviv, Israel  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 972-3-691-7691

Edgar Filing: InspireMD, Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On September 27, 2012, InspireMD, Inc. issued a press release announcing that the initial results from its MGuard™ for Acute ST Elevation Reperfusion (MASTER) Trial will be presented by Gregg M. Stone, MD, the MASTER Trial's chairman, on October 24, 2012 at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in Miami, Florida. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number	Description
99.1	Press release dated September 27, 2012.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

inspiremd, inc.

Date: October 3, 2012 By:     /s/ Craig Shore      
Name: Craig Shore  
Title: Chief Financial Officer

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press release dated September 27, 2012.